Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT538 + Daratumumab in AML
NCT04714372Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- Nov 2021
- Primary completion
- Jan 2024
- Modality
- Gene Editing, Gene Silencing, Patient-derived iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT538 in acute myeloid leukemia (AML) (4 arms), sponsored by Masonic Cancer Center. Primary endpoint: Dose Limiting Toxicity at 42 days. Started Nov 2021; status: completed.
02
Drugs
FT538
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04714372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04714372.